t quarterly reports on Form 10-Q. Readers are cautioned
not to place undue reliance on these forward-looking statements that speak
only as of the date of this release. Onyx undertakes no obligation to
update publicly any forward-looking statements to reflect new information,
events, or circumstances after the date of this release except as required
by law.
(See attached tables.)
ONYX PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(unaudited)
Three Months Ended Six Months Ended
------------------- ----------------
Jun. 30, Jun. 30,
-------- --------
2008 2007 2008 2007
---- ---- ---- ----
Net revenue from unconsolidated
joint business $30,199 $7,470 $67,937 $10,495
Operating expenses:
Research and development (1) 8,625 6,448 16,062 11,982
Selling, general and
administrative (1) 19,822 15,712 39,667 28,895
------ ------ ------ ------
Total operating expenses 28,447 22,160 55,729 40,877
------ ------ ------ ------
Income (loss) from operations 1,752 (14,690) 12,208 (30,382)
Investment income 2,662 3,864 7,933 7,361
------ ------ ------ ------
Income (loss) before income taxes 4,414 (10,826) 20,141 (23
'/>"/>
SOURCE Onyx Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1.
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes2.
China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results3.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML4.
XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20075.
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results6.
Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences7.
Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer8.
Poniard Pharmaceuticals Announces Participation in Upcoming Conferences9.
NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals10.
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)11.
Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs